HepFree India is an initiative of Kalavati Rajnikant Kanakia (KRK) Foundation. The overall objective of the initiative is to engage members of the general population through different avenues to increase awareness about Chronic Hepatitis B & C and to encourage active participation in the prevention, diagnosis, transmission and treatment of Chronic Viral Hepatitis.
The HepFree India – Hepatitis Free India (HFI) initiative involves a series of Awareness and Screening camps across the country. In the first phase HFI shall start its activities from Mumbai and gradually extend it to other districts of Maharashtra and India. These camps are intended to make people aware about the problem of Viral Hepatitis, ways to prevent it, complications and available treatment options.
HFI camps will also perform Hepatitis B & C tests by Rapid Card Tests to diagnose Hepatitis B & C early and guide infected individuals to panel of our specialists for further management. These tests would cost an individual approximately INR 6,00- 1,000 at private laboratories. HFI will conduct these tests free of charge.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close